Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/Akt Signaling Pathway

BACKGROUND: Oxaliplatin (OXA)-based chemotherapy is generally used to treat human cancers, whereas OXA resistance is a main obstacle for the treatment of colorectal cancer (CRC). Evidence has shown that tanshinone IIA (Tan IIA) could induce apoptosis in CRC cells. However, the role of combination of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Zhang, Yonggang, Ge, Tingrui, Xiang, Ping, Zhou, Jingyi, Tang, Shumin, Mao, Haibing, Tang, Qiang
Format: Artigo
Idioma:Inglês
Publicat: Dove 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6859961/
https://ncbi.nlm.nih.gov/pubmed/32009805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S217914
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars